Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

or indeed on the label' of other drugs in the PD-1/PD-L1 inhibitor class like Bristol-Myers Squibb's Opdivo (nivolumab). Merck is still plugging away with Keytruda though, and has two phase 3 ...

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Merck (NYSE:MRK) announced Friday detailed results from its Phase 3 AMBASSADOR trial, noting that its anti-PD1 therapy Keytruda cut the risk of disease recurrence or death by 31% after surgery in ...

Novel IGSF8 Plus Keytruda Evaluated in Phase 1 Trial for Solid Tumors April 18th 2024 Two immune checkpoint inhibitors are being evaluated together in a phase 1 trial for certain patients with ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy ... The EC approvals are based on results from the Phase 3 NRG-GY018 trial, also ...

Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in ...

TX an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, in ...